Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy.
Keshari S, Shavkunov AS, Miao Q, Saha A, Minowa T, Molgora M, Williams CD, Chaib M, Highsmith AM, Pineda JE, Alekseev S, Alspach E, Hu KH, Colonna M, Pauken KE, Chen K, Gubin MM. Keshari S, et al. Among authors: gubin mm. Cell Rep. 2024 Nov 26;43(11):114875. doi: 10.1016/j.celrep.2024.114875. Epub 2024 Oct 23. Cell Rep. 2024. PMID: 39446585 Free PMC article.
Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles.
He S, Gubin MM, Rafei H, Basar R, Dede M, Jiang X, Liang Q, Tan Y, Kim K, Gillison ML, Rezvani K, Peng W, Haymaker C, Hernandez S, Solis LM, Mohanty V, Chen K. He S, et al. Among authors: gubin mm. bioRxiv [Preprint]. 2024 May 14:2024.05.10.593433. doi: 10.1101/2024.05.10.593433. bioRxiv. 2024. Update in: iScience. 2024 May 23;27(6):110096. doi: 10.1016/j.isci.2024.110096. PMID: 38798470 Free PMC article. Updated. Preprint.
Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy.
Keshari S, Shavkunov AS, Miao Q, Saha A, Williams CD, Highsmith AM, Pineda JE, Alspach E, Hu KH, Pauken KE, Chen K, Gubin MM. Keshari S, et al. Among authors: gubin mm. bioRxiv [Preprint]. 2024 Jan 26:2023.12.20.570816. doi: 10.1101/2023.12.20.570816. bioRxiv. 2024. Update in: Cell Rep. 2024 Nov 26;43(11):114875. doi: 10.1016/j.celrep.2024.114875. PMID: 38187708 Free PMC article. Updated. Preprint.
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses.
He M, Roussak K, Ma F, Borcherding N, Garin V, White M, Schutt C, Jensen TI, Zhao Y, Iberg CA, Shah K, Bhatia H, Korenfeld D, Dinkel S, Gray J, Ulezko Antonova A, Ferris S, Donermeyer D, Lindestam Arlehamn C, Gubin MM, Luo J, Gorvel L, Pellegrini M, Sette A, Tung T, Bak R, Modlin RL, Fields RC, Schreiber RD, Allen PM, Klechevsky E. He M, et al. Among authors: gubin mm. Science. 2023 Feb 17;379(6633):eabg2752. doi: 10.1126/science.abg2752. Epub 2023 Feb 17. Science. 2023. PMID: 36795805 Free PMC article.
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.
Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Zhou Y, et al. Among authors: gubin mm. J Exp Med. 2023 Feb 6;220(2):e20221333. doi: 10.1084/jem.20221333. Epub 2022 Nov 11. J Exp Med. 2023. PMID: 36367776 Free PMC article.
The dynamics of an immunotherapy duo.
Shavkunov AS, Gubin MM. Shavkunov AS, et al. Among authors: gubin mm. Nat Cancer. 2022 Apr;3(4):376-378. doi: 10.1038/s43018-022-00362-5. Nat Cancer. 2022. PMID: 35484417 No abstract available.
BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy.
Salmon AJ, Shavkunov AS, Miao Q, Jarjour NN, Keshari S, Esaulova E, Williams CD, Ward JP, Highsmith AM, Pineda JE, Taneja R, Chen K, Edelson BT, Gubin MM. Salmon AJ, et al. Among authors: gubin mm. Cancer Immunol Res. 2022 May 3;10(5):597-611. doi: 10.1158/2326-6066.CIR-21-0129. Cancer Immunol Res. 2022. PMID: 35181783 Free PMC article.
34 results